Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

Clinical infectious diseases: an official publication of the Infectious Diseases Society of America

Volumn 33, Issue 7, 2001, Pages E57-61

  Soto, J ^a   Toledo, J ^a   Gutierrez, P ^b   Nicholls, R S ^c   Padilla, J ^d   Engel, J ^e   Fischer, C ^e   Voss, A ^f   Berman, J ^g  

^a Consorcio de Investigaciones Bioclinicas ^*  (Colombia)

^b XVII Brigada   (Colombia)

^c INSTITUTO NACIONAL DE SALUD   (Colombia)

^d Ministerio de Salud   (Colombia)

^e ASTA MEDICA AG   (Germany)

^f BAYER AG   (Germany)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; MILTEFOSINE; PHOSPHORYLCHOLINE;

ADULT; ARTICLE; CLINICAL TRIAL; COLOMBIA; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SKIN LEISHMANIASIS; SOLDIER; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIPROTOZOAL AGENTS; COLOMBIA; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MILITARY PERSONNEL; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

EID: 1342308517     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322689     Document Type: Article

References (0)